SEOUL – South Korean medical aesthetics company Hugel announced today its highest ever quarterly financial performance, with significant year-over-year (YoY) growth. The third quarter results showcased a revenue of KRW 84.8 billion and an operating profit of KRW 34.6 billion, marking a 20% and 39.5% increase in each category respectively compared to the same period last year.
The record figures were propelled by robust sales of Hugel’s botulinum toxin products, known as “Botulax” or “Letybo” internationally, and its HA filler line-up that includes “THE CHAEUM” (with products “Revolax”, “Dermalax”, and “Persnica”) as well as “BYRYZN”. The domestic market saw revenue skyrocket by over 140%, a surge attributed to aggressive marketing efforts and academic events. European operations also hit new highs in quarterly revenue, while the Asia-Pacific region experienced considerable growth.
Hugel’s derma cosmetic brand “WELLAGE” contributed to the strong performance with a 35% YoY growth. This success was credited to expanding distribution channels and introducing new products like the “Real Hyaluronic 100” line, which has significantly boosted sales.
Looking forward, Hugel is setting its sights on further global market penetration. Following recent marketing approval in Switzerland, the company is adjusting its strategy to dominate the botulinum toxin market. A revised distribution agreement with Croma in Europe will see Hugel regain operational rights for more product SKUs, excluding the 50-unit product.
The company is also preparing for sales in Canada after obtaining marketing approval there last year and is working towards securing the U.S. Food and Drug Administration’s (FDA) marketing approval in early next year. Additionally, plans are underway to launch products in Thailand, building on marketing approval received this past August.
Hugel’s ambitious strategy doesn’t stop there; it aims to capture a 20% market share in Europe within three years, eyeing expansion into markets like the Netherlands and Belgium. This comprehensive approach is expected to create synergy across Hugel’s aesthetic product portfolio and drive further growth.
InvestingPro data reveals Hugel’s impressive performance in the medical aesthetics industry. The company’s stock price has seen a steady increase over the last twelve months, reflecting its robust financial performance. The company’s P/E ratio, a key metric for investors to evaluate a company’s market value relative to its earnings, stands at a healthy 23.5 as of Q3 2023, indicating a strong market sentiment towards Hugel’s growth prospects.
InvestingPro Tips suggest that Hugel’s aggressive marketing efforts and its strategy to dominate the botulinum toxin market, particularly in Europe, are key factors driving its success. The company’s focus on expanding distribution channels and introducing new products is also a positive sign for investors. There are over 100 additional InvestingPro Tips available that provide insights into the company’s strategy and future prospects.
InvestingPro’s real-time data and tips offer valuable insights for those interested in the medical aesthetics industry and Hugel’s growth trajectory. Stay tuned to InvestingPro for more tips and data that can help you make informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.